Fighting cancer with precision and power.
Bicara Therapeutics is a clinical-stage biotechnology company developing first-in-class bifunctional biologics that combine tumor-targeting antibodies with tumor microenvironment modulators to treat solid tumors. Its bifunctional antibody platform is designed to deliver immunomodulatory payloads directly to the tumor site, enabling synergistic anti-tumor immune activity. The company is publicly traded (Nasdaq: BCAX) and advancing its lead programs through Phase 1b and Phase 3 clinical trials.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountFeb 2026
Sep 2024
Dec 2023
Mar 2023
Mar 2021
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
China's leading mRNA biotech company developing therapeutics for cancer and infectious diseases.
Late-stage biopharma using single-molecule tracking, AI, and engineering to discover and develop ...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
